Related Experiment Video
Updated: Jun 13, 2026

Ovarian Tissue Culture to Visualize Phenomena in Mouse Ovary
Published on: June 19, 2018
Identification of androgen receptor phosphorylation in the primate ovary in vivo
Iain J McEwan1, Dagmara McGuinness, Colin W Hay
1MRC Human Reproductive Sciences Unit, Queen's Medical Research Institute, 47 Little France Crescent, Edinburgh EH16 4TJ, Scotland, UK. iain.mcewan@abdn.ac.uk
Abstract:
The androgen receptor (AR) is a member of the nuclear receptor superfamily, and is important for both male and female reproductive health. The receptor is a target for a number of post-translational modifications including phosphorylation, which has been intensively studied in vitro. However, little is known about the phosphorylation status of the receptor in target tissues in vivo. The common marmoset is a useful model for studying human reproductive functions, and comparison of the AR primary sequence from this primate shows high conservation of serines known to be phosphorylated in the human receptor and corresponding flanking amino acids. We have used a panel of phosphospecific antibodies to study AR phosphorylation in the marmoset ovary throughout the follicular phase and after treatment with GNRH antagonist or testosterone propionate. In normal follicular phase ovaries, total AR (both phosphorylated and non-phosphorylated forms) immunopositive staining was observed in several cell types including granulosa cells of developing follicles, theca cells and endothelial cells lining blood vessels. Receptor phosphorylation at serines 81, 308, and 650 was detected primarily in the granulosa cells of developing follicles, surface epithelium, and vessel endothelial cells. Testosterone treatment lead to a modest increase in AR staining in all stages of follicle studied, while GNRH antagonist had no effect. Neither treatment significantly altered the pattern of phosphorylation compared to the control group. These results demonstrate that phosphorylation of the AR occurs, at a subset of serine residues, in a reproductive target tissue in vivo, which appears refractory to hormonal manipulations.
Insights
Androgen receptor (AR) phosphorylation occurs in marmoset ovaries in vivo. This reproductive process was studied using phosphospecific antibodies, revealing phosphorylation at specific sites in granulosa cells and endothelial cells.
Area of Science:
- Reproductive biology
- Molecular endocrinology
- Nuclear receptor signaling
Background:
- The androgen receptor (AR) is crucial for reproductive health in both sexes.
- While AR phosphorylation is studied in vitro, its in vivo status in reproductive tissues is largely unknown.
- The common marmoset serves as a valuable model for human reproductive functions due to high AR sequence conservation.
Purpose of the Study:
- To investigate the in vivo phosphorylation status of the androgen receptor (AR) in the marmoset ovary.
- To examine AR phosphorylation patterns during the follicular phase and in response to hormonal manipulation.
- To identify specific serine residues phosphorylated in the marmoset ovary.
Main Methods:
- Utilized phosphospecific antibodies to detect phosphorylated AR in marmoset ovarian tissues.
- Analyzed AR phosphorylation across the follicular phase.
- Assessed the effects of GNRH antagonist and testosterone propionate treatments on AR phosphorylation.
Main Results:
- Total AR staining was observed in granulosa cells, theca cells, and endothelial cells in normal follicular phase ovaries.
- AR phosphorylation at serines 81, 308, and 650 was detected in granulosa cells, surface epithelium, and endothelial cells.
- Testosterone treatment increased total AR staining, but neither testosterone nor GNRH antagonist significantly altered AR phosphorylation patterns.
Conclusions:
- Demonstrates that androgen receptor (AR) phosphorylation occurs in a reproductive target tissue in vivo.
- Specific serine residues of AR are phosphorylated in the marmoset ovary.
- AR phosphorylation in the marmoset ovary appears refractory to short-term hormonal manipulations with testosterone or GNRH antagonist.

